Impact of Toll-like receptor 4 polymorphisms on risk of cancer

Human Immunology

Volumn 72, Issue 2, 2011, Pages 193-206

  Kutikhin, Anton G ^a  

^a KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cancer; Immune response; Inflammation; Single nucleotide polymorphism; Toll like receptor 4

Indexed keywords

CYTOKINE; TOLL LIKE RECEPTOR 4;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIGEN ANTIBODY REACTION; BREAST CANCER; CANCER GROWTH; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; HUMAN; IMMUNE RESPONSE; LIGAND BINDING; NASOPHARYNX CARCINOMA; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

BLOOD-BORNE PATHOGENS; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TH1-TH2 BALANCE; TOLL-LIKE RECEPTOR 4;

EID: 78651254547     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.11.003     Document Type: Review

References (134)

1. Hashimoto C., Hudson K.L., Anderson K.V. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988, 52:269-279.
2. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
3. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
4. Huyton T., Rossjohn J., Wilce M. Toll-like receptors: Structural pieces of a curve-shaped puzzle. Immunol Cell Biol 2007, 85:406-410.
5. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
6. Opal S.M., Esmon C.T. Bench-to-bedside review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003, 7:23-38.
7. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
8. Yu L., Wang L., Li M., Zhong J., Wang Z., Chen S. Expression of Toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 2010, [Epub ahead of print].
9. Lagos D., Vart R.J., Gratrix F., Westrop S.J., Emuss V., Wong P.P., et al. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 2008, 4:470-483.
10. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007, 44:2850-2859.
11. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
12. Molteni M., Marabella D., Orlandi C., Rossetti C. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 2006, 235:75-83.
13. Szczepanski M.J., Czystowska M., Szajnik M., Harasymczuk M., Boyiadzis M., Kruk-Zagajewska A., et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009, 69:3105-3113.
14. Webb R.N., Cruse J.M., Lewis R.E. Decreased TLR4 gene expression in leukemic leukocyte populations. Exp Mol Pathol 2009, 87:117-126.
15. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 274:10689-10692.
16. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
17. Roeder A., Kirschning C.J., Rupec R.A., Schaller M., Weindl G., Korting H.C. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004, 42:485-498.
18. Armant M.A., Fenton M. Toll-like receptors: A family of pattern recognition receptors in mammals. Genome Biol 2002, 3:3011-3016.
19. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of Toll-like receptor mediated immune response. Nat Rev Immunol 2005, 5:446-458.
20. Ohashi K., Burkart V., Flohe S., Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
21. Vabulas R.M., Ahmad-Nejad P., Ghose S., Kirschning C.J., Issels R.D., Wagner H. HSP70 as endogenous stimulus of toll/interleukin-1 receptor signal pathway. J Biol Chem 2002, 277:15107-15112.
22. Warger T., Hilf N., Rechtsteiner G., Haselmayer P., Carrick D.M., Jonuleit H., et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 2006, 281:22545-22553.
23. Lapteva N., Aldrich M., Rollins L., Ren W., Goltsova T., Chen S.Y., Huang X.F. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009, 17:1626-1636.
24. Säemann M.D., Weichhart T., Zeyda M., Staffler G., Schunn M., Stuhlmeier K.M., et al. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 2005, 115:468-475.
25. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005, 115:2223-2233.
26. Smiley S.T., King J.A., Hancock W.W. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 2001, 167:2887-2894.
27. Guillot L., Balloy V., McCormack F.X., Golenbock D.T., Chignard M., Si-Tahar M. Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002, 168:5989-5992.
28. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002, 195:99-111.
29. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276:10229-10233.
30. Johnson G.B., Brunn G.J., Kodaira Y., Platt J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparin sulfate by Toll-like receptor 4. J Immunol 2002, 168:5233-5239.
31. Tsan M.F., Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004, 76:514-519.
32. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., et al. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
33. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
34. Kim H.M., Park B.S., Kim J.I., Kim S.E., Lee J., Oh S.C., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007, 130:906-917.
35. Miggin S.M., O'Neill L.A. New insights into the regulation of TLR signaling. J Leukoc Biol 2006, 80:220-226.
36. Pasare C., Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2005, 22:397-399.
37. El-Omar E.M., Ng M.T., Hold G.L. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252.
38. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9:57-63.
39. Cook D.N., Pisetski D.S., Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004, 5:975-979.
40. Seya T., Akazawa T., Uehori J., Matsumoto M., Azuma I., Toyoshima K. Role of Toll-like receptor and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003, 23:4369-4376.
41. Okamoto M., Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003, 50:9-24.
42. Tsan M.F. Toll-like receptors, inflammation, and cancer. Semin Cancer Biol 2006, 16:32-37.
43. Killeen S.D., Wang J.H., Andrews E.J., Redmond H.P. Exploitation of the Toll-like receptor system in cancer: A doubled-edged sword?. Br J Cancer 2006, 95:247-252.
44. Chen R., Alvero A.B., Silasi D.-A., Mor G. Inflammation, cancer and chemoresistance: Taking advantage of the Toll-like receptor signaling pathway. Am J Reprod Immunol 2007, 57:93-107.
45. Kinlen L. Infections and immune factors in cancer: The role of epidemiology. Oncogene 2004, 23:6341-6348.
46. Stevens V.L., Hsing A.W., Talbot J.T., Zheng S.L., Sun J., Chen J., et al. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008, 123:2644-2650.
47. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., et al. Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003, 307:906-922.
48. Tierney M.J., Medcalf R.L. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001, 276:13675-13684.
49. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., Gejman P.V. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003, 12:205-216.
50. Thomas K.H., Meyn P., Suttorp N. Single nucleotide polymorphism in 5'-flanking region reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol 2006, 291:L386-L390.
51. Zysow B.R., Lindahl G.E., Wade D.P., Knight B.L., Lawn R.M. C/T polymorphism in the 5'untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995, 15:58-64.
52. Bell J.K., Mullen G.E.D., Leifer C.A., Mazzoni A., Davies D.R., Segal D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003, 24:528-533.
53. Johnson C.M., Lyle E.A., Omueti K.O., Stepensky V.A., Yegin O., Alpsoy E., et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007, 178:7520-7524.
54. Smirnova I., Hamblin M.T., McBride C., Beutler B., Di Rienzo A. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics 2001, 58:1657-1664.
55. Ferwerda B., McCall M.B., Verheijen K., Kullberg B.J., van der Ven A.J., Van der Meer J.W., Netea M.G. Functional consequences of Toll-like receptor 4 polymorphisms. Mol Med 2008, 14:346-352.
56. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., et al. Analysis of TLR4 polymorphic variants: New insights into TLR4/MD-2/CD14 stoichiometry, structure and signaling. J Immunol 2006, 177:322-332.
57. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
58. Schröder N.W., Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005, 5:156-164.
59. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
60. Ferwerda B., McCall M.B., Alonso S., Giamarellos-Bourboulis E.J., Mouktaroudi M., Izagirre N., et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007, 104:16645-16650.
61. Wu M.S., Cheng T.Y., Shun C.T., Lin M.T., Chen L.C., Lin J.T. Functional polymorphisms of CD14 and Toll-like receptor 4 in Taiwanese Chinese with Helicobacter pylori-related gastric malignancies. Hepato Gastroenterol 2006, 53:807-810.
62. Hishida A., Matsuo K., Goto Y., Mitsuda Y., Hiraki A., Naito M., et al. Toll-like receptor 4 +3725G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 2009, 14:47-53.
63. Kim Y.S., Hwang Y.J., Kim S.Y., Yang S.M., Lee K.Y., Park IeB. Rarity of TLR4 Asp299Gly and Thr399Ile polymorphisms in the Korean population. Yonsei Med J 2008, 49:58-62.
64. Zheng B., Wei C., Shou T., Li Q., Yang M., Yi L., et al. A unique display of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in non-Han Chinese Hani population. Int J Immunogenet 2010, 37:43-46.
65. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
66. Rallabhandi P., Awomoyi A., Thomas K.E., Phalipon A., Fujimoto Y., Fukase K., et al. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: Combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J Immunol 2008, 180:1139-1147.
67. Mockenhaupt F.P., Cramer J.P., Hamann L., Stegemann M.S., Eckert J., Oh N.R., et al. Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. J Commun Disord 2006, 38:230-245.
68. Awomoyi A.A., Rallabhandi P., Pollin T.I., Lorenz E., Sztein M.B., Boukhvalova M.S., et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007, 179:3171-3177.
69. Yaa M.N., Paolo P., Peter S., Eric P.G., Jaya S., Papanicolaou G.A. Toll-like receptor 4 polymorphisms and risk of gram-negative bacteremia after allogeneic stem cell transplantation. A prospective pilot study. Biol Blood Marrow Transplant 2009, 15:1130-1133.
70. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032.
71. Van der Graaf C.A., Netea M.G., Morré S.A., Den Heijer M., Verweij P.E., Van der Meer J.W., Kullberg B.J. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006, 17:29-34.
72. Pabst S., Baumgarten G., Stremmel A., Lennarz M., Knüfermann P., Gillissen A., et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006, 143:420-426.
73. Montes A.H., Asensi V., Alvarez V., Valle E., Ocaña M.G., Meana A., et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006, 143:404-413.
74. Schröder N.W., Meister D., Wolff V., Christan C., Kaner D., Haban V., et al. Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 gene. Genes Immun 2005, 6:448-451.
75. Browning B.L., Huebner C., Petermann I., Gearry R.B., Barclay M.L., Shelling A.N., Ferguson L.R. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene?. Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007, 102:2504-2512.
76. Brand S., Staudinger T., Schnitzler F., Pfennig S., Hofbauer K., Dambacher J., et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005, 11:645-652.
77. Edfeldt K., Bennet A.M., Eriksson P., Frostegård J., Wiman B., Hamsten A., et al. Association of hypo-responsive Toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004, 25:1447-1453.
78. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
79. Matysiak-Budnik T., Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006, 42:708-716.
80. Trejo-de la O.A., Torres J., Pérez-Rodríguez M., Camorlinga-Ponce M., Luna L.F., et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008, 129:333-340.
81. Schmausser B., Andrulis M., Endrich S., Lee S.K., Josenhans C., Müller-Hermelink H.K., Eck M. Expression and subcellular distribution of Toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004, 136:521-526.
82. Kato I., Canzian F., Plummer M., Franceschi S., van Doorn L.J., Vivas J., et al. Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signalling and gastric precancerous lesions in a population at high risk for gastric cancer. Dig Dis Sci 2007, 52:254-261.
83. Smith M.F., Mitchell A., Li G., Ding S., Fitzmaurice A.M., Ryan K., et al. TLR2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kB activation and chemokine expression by epithelial cells. J Biol Chem 2003, 278:33552-33560.
84. Hold G.L., Rabkin C.S., Chow W.H., Smith M.G., Gammon M.D., Risch H.A., et al. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
85. Achyut B.R., Ghoshal U.C., Moorchung N., Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007, 68:901-907.
86. Rigoli L., Bella DI C., Fedele F., Procopio V., Amorini M., et al. TLR4 and NOD2/CARD15 Genetic Polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res 2010, 30:513-517.
87. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
88. Sakamoto T., Saito H., Tatebe S., Tsujitani S., Ozaki M., Ito H., Ikeguchi M. Interleukin-10 expression significantly correlates with minor CD8+ T-cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 2006, 118:1909-1914.
89. Klebanoff S.J. Myeloperoxidase. Proc Assoc Am Physicians 1999, 111:383-389.
90. Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 1998, 64:275-290.
91. Santini D., Angeletti S., Ruzzo A., Dicuonzo G., Galluzzo S., Vincenzi B., et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008, 154:360-364.
92. Garza-Gonzalez E., Bosques-Padilla F.J., Mendoza-Ibarra S.I., Flores-Gutierrez J.P., Maldonado-Garza H.J., Perez-Perez G.I. Assessment of the Toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007, 7:70.
93. Ohara T., Morishita T., Suzuki H., Hibi T., Heterozygous T. 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of Toll-like receptor 4 in patients with poorly differentiated gastric adenocarcinomas. Int J Mol Med 2006, 18:59-63.
94. De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999, 155:1985-1992.
95. De Marzo A.M., Meeker A.K., Zha S., Luo J., Nakayama M., Platz E.A., et al. Human prostate cancer precursors and pathobiology. Urology 2003, 62:55-62.
96. Chen Y.C., Giovannucci E., Lazarus R., Kraft P., Ketkar S., Hunter D.J. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005, 65:11771-11778.
97. Cheng I., Plummer S.J., Casey G., Witte J.S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16:352-355.
98. Song J., Kim D.Y., Kim C.S., Kim H.J., Lee D.H., Lee H.M., et al. The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet 2009, 190:88-92.
99. Wang M.H., Helzlsouer K.J., Smith M.W., Hoffman-Bolton J.A., Clipp S.L., Grinberg V., et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE. Prostate 2009, 69(II):874-885.
100. Zheng S.L., Augustsson-Bälter K., Chang B., Hedelin M., Li L., Adami H.O., et al. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study. Cancer Res 2004, 64:2918-2922.
101. Balistreri C.R., Caruso C., Carruba G., Miceli V., Campisi I., Listì F., et al. A pilot study on prostate cancer risk and pro-inflammatory genotypes: Pathophysiology and therapeutic implications. Curr Pharm Des 2010, 16:718-724.
102. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
103. Robins H., Li Y., Padgett R.W. Incorporating structure to predict microRNA targets. Proc Natl Acad Sci U S A 2005, 102:4006-4009.
104. Conne B., Stutz A., Vassalli J.D. The 3' untranslated region of messenger RNA: A molecular "hotspot" for pathology?. Nat Med 2000, 6:637-641.
105. Song C., Chen L.Z., Zhang R.H., Yu X.J., Zeng Y.X. Functional variant in the 3'-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther 2006, 5:1285-1291.
106. Lindström S., Hunter D.J., Grönberg H., Stattin P., Wiklund F., Xu J., et al. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev 2010, 19:873-876.
107. McConnell B.B., Yang V.W. The role of inflammation in the pathogenesis of colorectal cancer. Curr Colorectal Cancer Reprod 2009, 5:69-74.
108. Cario E., Podolsky D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000, 68:7010-7017.
109. Hausmann M., Kiessling S., Mestermann S., Webb G., Spöttl T., Andus T., et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002, 122:1987-2000.
110. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease?. The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-992.
111. Boraska Jelavić T., Barisić M., Drmic Hofman I., Boraska V., Vrdoljak E., Peruzović M., et al. Polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006, 70:156-160.
112. Landi S., Gemignani F., Bottari F., Gioia-Patricola L., Guino E., Cambray M., et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed 2006, 5:15.
113. Gismera C.S., Aladrén B.S. Inflammatory bowel diseases: A disease (s) of modern times?. Is incidence still increasing?. World J Gastroenterol 2008, 14:5491-5498.
114. Sincić B.M., Vucelić B., Persić M., Brncić N., Erzen D.J., Radaković B., et al. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol 2006, 41:437-444.
115. Tsilidis K.K., Helzlsouer K.J., Smith M.W., Grinberg V., Hoffman-Bolton J., Clipp S.L., et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 2009, 20:1739-1751.
116. Purdue M.P., Lan Q., Wang S.S., Kricker A., Menashe I., Zheng T.Z., et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009, 30:275-281.
117. Forrest M.S., Skibola C.F., Lightfoot T.J., Bracci P.M., Willett E.V., Smith M.T., et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006, 134:180-183.
118. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006, 7:615-624.
119. Hellmig S., Fischbach W., Goebeler-Kolve M.E., Fölsch U.R., Hampe J., Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005, 46:869-872.
120. Türe-Ozdemir F., Gazouli M., Tzivras M., Panagos C., Bovaretos N., Petraki K., et al. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2008, 28:3697-3700.
121. Aldred M.A., Eng C. SNPing at nasopharyngeal cancer susceptibility: For whom the bell TOLLs. Cancer Biol Ther 2006, 5:1292-1293.
122. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: Comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 2000, 91:1233-1240.
123. Pandey S., Mittal R.D., Srivastava M., Srivastava K., Singh S., Srivastava S., Mittal B. Impact of Toll-like receptors. TLR [2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol 2009, 114:501-505.
124. Modugno F., Ness R.B., Chen C., Weiss N.S. Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiol Biomarkers Prev 2005, 14:2840-2847.
125. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., Scott R.J. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer 2010, 10:382.
126. Zitvogel L., Tesniere A., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of anticancer chemotherapy. Bull Acad Natl Med 2008, 192:1469-1487.
127. Apetoh L., Ghiringhelli F., Tesniere A., Criollo A., Ortiz C., Lidereau R., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220:47-59.
128. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
129. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290:C917-C924.
130. Apetoh L., Tesniere A., Ghiringhelli F., Kroemer G., Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68:4026-4030.
131. Etokebe G.E., Knezević J., Petricević B., Pavelić J., Vrbanec D., Dembić Z. Single-nucleotide polymorphisms in genes encoding Toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol. Biomarkers 2009, 13:729-734.
132. Peng S.L. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005, 17:230-236.
133. Tulic M.K., Hurrelbrink R.J., Prele C.M., Laing I.A., Upham J.W., Le Souef P., et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007, 179:132-140.
134. Srivastava K., Srivastava A., Kumar A., Mittal B. Significant association between Toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int 2010, 30:1067-1072.